Disclosure. Robert Fischer Fertility Centre Hamburg Hamburg, Germany. Declared no potential conflict of interest.
|
|
- Barbara Singleton
- 5 years ago
- Views:
Transcription
1
2 Disclosure Robert Fischer Fertility Centre Hamburg Hamburg, Germany Declared no potential conflict of interest.
3 Updates on Luteal Phase supplementation Kiev Robert Fischer MVZ Fertility Center Hamburg ISO 9001:2015
4 Outline Why is Luteal Phase support (LPS) required Luteal Phase after hcg triggering New challenges:gnrh-a triggering The more physiological LPS The evidence - The new option Conclusions
5 Human Corpus Luteum P4 secretion is maximum during mid-luteal phase inducing a serum P4 of nmol/l (13-19 ng/dl) in natural cycle Sufficient P4 essential for endometrium decidualisation preceding implantation Soules et al. Obstet Gynecol 1988;71:
6 LH-P4 Pulse PULSATILE LH Filicori et al., 1984 Stimulation of steroidogenesis by the CL Stimulation of cytokines and growth factors that take part in implantation Extragonadal activation of endometrial LH receptors and enhancement of implantation
7 Progesterone is antiapoptotic for the endometrium No Tx Progesterone increases the immunostaining of the antiapoptotic bcl-2 P4 Lovely et al., 2005 TUNEL labeling apoptotic bodies D26 endometrium with P or placebo treatment
8 Is LPS required? LP in ALL stimulated ART cycles is abnormal (vs 8.1% natural cycles) Main reason is the inhibition of LH secretion (LH pulse frequency and amplitude) due to supraphysiological steroid levels and distruption of the feedback mechanisms of the Hypothalamo-pituitary-ovarian axis. an insufficient progesterone concentration at the time of implantation or during early pregnancy may cause early pregnancy loss. Tavaniotou, 2001; Fauser and Devroey, 2003;Edwards, 1980; Fatemi, 2007
9 Luteal phase of stimulated cycles abnormal Supraphysiologic steroid levels (due to multifollicular development) inhibits LH secretion Low LH levels causes luteolysis, shortened luteal phase, and may result in implantation failure Mid-cycle LH levels Natural cycle 6.0 IU/L hcg trigger 0.2 IU/L GnRHa trigger 1.5 IU/L P4 requirement during LP of stimulated cycles greater than natural cycle Jones 1996; Albano et al. Fertil Steril 1998;70:357-9; Tavaniotou et al. Hum Reprod Update 2000;6:139-48; Fauser & Devroey. Trends Endocrinol Metab 2003;14:236-42; Trinchard-Lugan et al. Reprod Biomed Online. 2002;4:106-15; Sherbahn 2013; Humaidan et al. Hum Reprod 2005;20:
10 Pregnancy loss (%) Higher Progesterone Level Reduce Pregnancy Loss Pregnancy loss in relation to the mid-luteal phase progesterone levels in women undergoing ovulation with an agonist trigger Results from four independent studies Results from four independent studies Humaidan et al. (2005) Hum Reprod. 20: Humaidan et al. (2010) Fertil Steril. 93: Engmann et al. (2008) Fertil Steril. 89:84-91 Humaidan et al. (2013) PMID: Mid-luteal phase progesterone levels (nmol/l) Yding Andersen & Andersen, RBMOnline, 2014; 28:552
11 Mid-luteal Progesterone levels are associated with increased pregnancy rates Viable pregnancies had significantly higher mean P 4 levels in the early luteal phase than non-pregnant. 73% of viable pregnancies, 42% of clinical abortions and 20% of preclinical abortions had a P 4 level exceeding 95 nmol/l in the mid-luteal phase (Liu et al., 1995) A significant positive association between the mean P 4 concentration during the luteal phase and the clinical pregnancy rate in a study of 544 women undergoing IVF treatment (Mitwally MF et al., 2010) A significant higher P 4 concentration in patients that became pregnant compared to those who did not (Ellenborgen A et al., 2004) Yding Andersen & Andersen, RBMOnline, 2014; 28:552
12 Arce J et al., RBMOnline, 2011;22:449 Progesterone Level is Linked to Live Birth Live birth rate associated with the mid-luteal progesterone concentration >32-48 >48-80 > >127 None of the 53 women with a progesterone concentration below 25 nmol/l had a clinical pregnancy and were not included in the present analysis
13 Mid-Luteal Phase Progesterone Level as Predictor of Live Birth Rate Vaginal progesterone average level ~ 37 nmol/l Vaginal progesterone Cmax ~ 46 nmol/l Prediction of the chance of a live birth based on the mid-luteal progesterone concentration (multivariate logistic regression model) Arce J et al., RBMOnline, 2011;22:449
14
15 LPS REGIMENS AFTER hcg TRIGGER AND FRESH ET Outcome Measure: LBR or OPR Progesterone vs. hcg (alone or +P): No difference (5 RCT; 833 women; OR=0.95; 95% CI ) Lower OHSS with P alone (5 RCT; 1,293 women; OR=0.46; 95% CI ) Progesterone vs. P + estrogens: No difference (9 RCT; 1,651 women; OR=1.12; 95% CI ) Progesterone vs. P + GnRH agonist: Lower P-only group (9 RCT; 2,861 women; OR=0.62; CI ; Low quality) van der Linden et al Cochrane 2015 van der Linden et al, Cochrane Database Syst Rev 2015:CD009154
16 Routes of progesterone administration Oral extensively metabolized; systemic side effects; low bioavailability Intramuscular effective but less convenient (pain, occasional sterile abcess; oil allergic reaction) Subcutaneous few clinical trials Rectal Not widely accepted; few clinical trials Vaginal as effective as IM injection; self administration Gibbons et al. Fertil Steril 1998;69:96-101; Ludwig & Diedrich. Acta Obs Gyn Scand. 2001; 80:452-66; Penzias Fertil Steril. 2002;77:318-23; Lockwood et al. Fertil Steril 2014; 101:
17 Progesterone regimens LPS after hcg trigger and FRESH ET Oral vs IM Vaginal/rectal vs. IM Vaginal/rectal vs. Oral Low-dose vs. High-dose vaginal Short (Early cessation) vs. Long protocol Micronized vs. Synthetic Vaginal ring vs. Gel Vaginal vs. Subcutaneous OHSS rates (Oral vs. IM; Low-dose vs. High-dose) 45 RCT; N=13,814 women Odds ratios not Significantly different Quality of Evidence varied from lowquality to very lowquality van der Linden et al, Cochrane Database Syst Rev 2015:CD009154
18 ng/ml ng Pg/mg protein Pharmacokinetics data: vaginal route vs IM Plasma progesterone concentrations in steady state USE OF EXOGENOUS PROGESTERONE Vaginal progesterone provide 4x200 mg/d2x50 mg/d Vaginal Pg IM Pg Progesterone concentrations in uterine tissue in steady state 8 steady state concentrations 6around ng/ml in circulation Miles A et al, Fertil Steril 1994; 62: First uterine pass effect / targeted delivery Cicinelli E et al, Obstet Gynecol 2000; 95: x200 mg/d Vaginal Pg 2x50 mg/d IM Pg
19 hcg/lh (IU/L) The exogenous hcg bolus trigger and the natural/gnrha trigger induced final maturation of follicles OPU OPU+2 OPU+4 OPU+6 OPU+7 o IU hcg o Natural mid-cycle surge of LH o GnRHa trigger induced mid-cycle surge of LH Time (days)
20 Progesterone (nmol/l) Levels of progesterone in the luteal phase following the natural menstrual cycle or by the use of hcg bolus trigger IU hcg Natural mid-cycle surge Days after OPU
21 The hcg bolus trigger impacts on the luteal phase Due to the high concentrations of progesterone and oestradiol the pituitary is inactivated whether down-regulated or not no LH output There is a gap of hcg (LH-like activity) in the mid-luteal phase coinciding with the crucial time of implantation Trigger Day 6 Day 8 Day 14 On the other hand the hcg bolus trigger results in a strong luteotropic signal early in the luteal phase hcg The concentration GnRHa of progesterone peaks in the LH early activity luteal deficiency phase period and will advance the endometrium Luteal phase length (days) Yding Andersen & Andersen, RBMOnline 2014;28: h LH activity deficiency period
22 number of cycles Histological dating Histological dating in natural and stimulated cycles </=3 days > 3 days 1 0 GnRH-agonists P < 0.05 P< P<0.05 (group) P< (interaction) Pregnant </=3 days > 3 days Histological dating GnRH-antagonists Natural cycle Not Pregnant Stimulated cycle Day 5 Day 0 Day 2 Day 7 Luteal day Bourgain et al, Fertil Steril 2002
23 In GnRH antagonist/fsh cycles, advanced endometrial maturation on the day of oocyte retrieval correlates with altered gene expression Van Vaerenbergh I, Van Lommel L, Ghislain V, In't Veld P, Schuit F, Fatemi HM, Devroey P, Bourgain C. According to Noyes' criteria, all endometria taken on the day of oocyte retrieval showed an advanced maturation, ranging from +d2 to +d4. The patients with a subsequent clinical pregnancy all showed a histological dating corresponding to +d2 or +d3. When comparing endometria +d2-3 to +d4, the microarray results showed a differential expression of 2550 probe sets. Significantly up-regulated genes were SERPINB6, FOXO3A, SOX17 and CDC42. Down-regulated genes of interest were NRP1, HOXA10 and OSF2.
24 The wide-genomic approach demonstrates a 2-day difference on the cluster of genes governing endometrial receptivity 15k 8x15K Day LH/hCG+7
25 Too much of the good? Experimental evidence suggests prolonged exposure to hcg is detrimental to endometrial receptivity. (Evans & Salamonsen, Hum.Rerod.2013). This study found that chronic exposure to normal hcg in vitro mediated a down-regulation of LHR in the endometrial epithelial cells and renders cells refractory to acute hcg. Evidence indicates that supra-physiological levels of hcg during the mid-luteal phase may interfere with successful implantation.
26 The Role of Hyperglycosylated hcg (H-hCG) A form of hcg that becomes considerably more glycosylated than normal hcg -makes the H-hCG fold in a way different to normal hcg, leading to biological properties that normal hcg does not possess. In addition to activating the LHR, the H-hCG also acts as a TGF-β antagonist (Cole, 2012). Almost all the hcg secreted from the implanting blastocyst is H-hCG and none is normal hcg, while normal hcg only takes over later on during pregnancy. Studies show that it is the deficiency of H-hCG that can cause incomplete blastocyst implantation or pregnancy failures, biochemical pregnancies and miscarriages (Cole, 2012). It may also be speculated that just when the implanting embryo starts to secrete almost exclusively H-hCG in very small quantities, the presence of normal hcg of around IU/L attenuates successful implantation because it may interfere with the specific actions mediated by H-hCG.
27 The new challenge: GnRH agonist for triggering of ovulation and Fresh E.T. First trials low clinical pregnancy rate high early pregnancy loss (Humaidan et al., 2005; Kolibianakis et al., 2005 Griesinger et al., Fertil Steril 2007; Hum. Rep. Update 2006) Low live birth rate after GnRHa versus hcg triggering (Griesinger et al., Fertil Steril 2007) Low reproductive outcome attributed to a luteal phase insufficiency despite supplementation with progesterone and estradiol GnRHa triggering leads to significantly reduced total amounts of LH released by the pituitary due to profile and duration of surge. (Gonen et al., 1990; Itskovitz et al., 1991) LH mean mid-luteal phase 6.0 IU/l in natural cycle 0,2 IU/I hcg trigger (Tavaniotou and Devroey 2003) 1.5 IU/l in GnRH-a group (Humaidan et al, 2005)
28 Serum concentrations of LH (hcg), FSH, E2, and P ( during triggering of final stages of oocyte maturation with two GnRH agonist or hcg Trigger Day 6 Day 8 Day 14 hcg GnRHa 28-32h Fauser B C et al. JCEM 2002;87: by Endocrine Society LH activity deficiency period LH activity deficiency period Luteal phase length (days)
29 Different Strategies for Lut.Phase Support (after GnRH-a Triggering) E2+Progesterone :(i.m.) high dose until 10 weeks pregnancy HCG :Multi Low-Dose 450 I.U. (Krause et al. 2006) (Engmann et al. 2008) Single- Dose 1500 I.U. /Double Dose (Humaidan et al.2010;2013) Dual Triggering (GnRHa+1000 I.U. hcg,if E2<4000pg/ml) (Shapiro et al.,2011; Engmann et al., 2012 ) Daily Micro-Dose (125 I.U.) hcg (C.Y.Andersen et al. 2015)) Luteal Phase Coasting (Kol et al.2016;fatemi et al.2017&2018) Rec LH: Multiple Dose 300 I.U. (Papanikolaou et al. 2011) GnRH Agonist :Multiple Dose daily (Pirard et al. 2006,2015) (Bar Hava et al. 2016)
30 Anatomy of progesterone delivery to the uterus Progesterone concentrations in sheep during the luteal phase Mean P 4 concentration in the ovarian vein was 800-fold higher than mean jugular venous levels Samples from ovarian veins contralateral to CL-bearing ovaries showed a mean P 4 concentration 30 times lower (ipsilateral: 1037 ±138; contralateral: 30 ±11 ng/ml; P < 0.001) Mean progesterone concentration in the uterine vein was approximately 30-fold higher than in jugular and similar in both uterine horns Ovarian production is more likely to cause a direct uterine effect than Vaginal route supplementation Abecia J et al., Anim. Reprod. Science, 1997;48:209
31 This is a proof-of-concept study conducted as a three arm RCT with a total of 93 patients Oestradiol (nmol/l) Progesterone (nmol/l) hcg (IU/L) Control Group1 Group 2 Control Group1 Group 2 Control Group1 Group 2 No. women ANOVA ANOVA ANOVA Day of OT 7.0 ± ± ±1.0 P> ± ± ±0.2 P>0.10 NM 4.8 ± ±0.5 P>0.10 Day of OPU NM NM NM 36.7 ± ± ±1.0 P< ± ±0.2 2,2 ±0.2 P<0.001 Day of OPU ± ±0.8 6,8 ±0.6 P= ± ± ±24 P= ± ± ±0.3 P=0.014 Yding Andersen et al., Hum Rep 2015;30:2387
32 hcg (IU/L) hcg during the luteal phase with different dosing 125 IU hcg daily IU hcg on OPU and OPU IU hcg on ovulation trigger GnRHa trigger induced mid-cycle surge of LH OPU OPU+2 OPU+4 OPU+6 OPU+7 Time (hours)
33 A new concept of Luteal support By courtesy of C. Yieding Andersen & T. Kelsey
34 Reproductive outcome of IVF/ICSI treatment in following the antagonist protocol and receiving GnRHa trigger for final oocyte maturation. 100 IU hcg daily No exogenous P4 (1 day after OPU for 9 days) Bolus hcg (1.500 IU) (OPU + individualized OPU 5) 800 mg P4 vag (Ultrogest) Period of treatment June Oct Jan. Oct NA No. of cycles/women 94/84 150/127 NA P-value Age (years) ± ± 0.33 P>0.10* Days of stimulation 8.5 ± ± 0.07 P>0.10* FSH consumption (IU) 2069 ± ± 59 P>0.10* No. oocytes (per cycle) 9.36 ± ± 0.55 P>0.10* Normally fertilized (MII oocyte) 478/749 (64%) 925/1411 (66%) P>0.10** Cryopreserved: 2PNs/embryos 44/65 133/74 NA No. Embryos for culture NA No. Embryos used for ET 132/80 (1.7) 234/135 (1.7) P>0.10** C.Yding Andersen,R.Fischer et al., JARG, 2016; PMID:
35 GnRH-a triggering for ovulation and LPS with only Mini hcg ( 100 IE s.c. OPU+1 until OPU +9) (<18 Follikel >12mm) 100 IE hcg daily no exogenous P4 (Start 1 day after OPU for 9 days) Bolus hcg (1.500 IE) (OPU + individualised OPU 5) +800 mg P4 vag (Ultrogest) P-value Cycles/Women Age 94/ ± / ± 0.33 NA P > 0.10 Patients with ET (% /cycle) 80 (85 %) 135 (90 %) P > 0.10 Nr. pos. hcg (% of ETs) 44 (55 %) 72 (53 %) P > 0.10 Biochemical Pregnancies 2 /44 (4.5 %) 13/72 (18,1 %) P = 0.02 Clinical Pregnancies(%) 42 (53 %) 59 (44 %) P > 0.10 Clinical Miscarriage (%) 3/42 (7.1 %) 10/59 (17 %) P = 0.09 Total Pregnancy Losses 5/44 (11.5 %) 23/72 (31.9 %) P = Ongoing Preg. Day 5 ET 47/75 (63%) 32/64 (50%) P= OHSS 1 Late Onset-mild 0 NA Yding Andersen, Fischer JARG, 2016;
36 100 IU hcg( OPU+1 Until OPU+9 ) F.C.H. personal DATA (7/ /2017) n=647 Age Group: <= >= 40 Age 28,38 ± 1,77 (48) 33,37 ± 1,37 (178) 37,80 ± 1,09 (220) 41,88 ± 1,93 (201) Mean Nr. Cycles 1,60 ± 1,18 (48) 2,22 ± 1,81 (178) 2,71 ± 2,62 (220) 3,46 ± 2,73 (201) BMI 24,54 ± 4,01 (46) 23,74 ± 4,43 (178) 23,17 ± 3,63 (220) 22,60 ± 3,24 (201) Cycles Freeze-All (FA) 10 (20,8%) 38 (21,6%) 20 (9,2%) 12 (6,0%) PBGT (nr.pregnant) 10 (20,8%) (3) 50 (28,4%) (18) 129 (59,4%) (47) 169 (84,5%) (33) ETs (%/without FA) 33 (86,8%) 128 (92,8%) 173 (87,8%) 108 (57,4%) CPR (%/ET) 19 (59%) 82 (64,1%) 87 (50,3%) 40 (37%) Twin(%/Pregnancy) 5 (26,3%) 28+1 (35,4%) 25 (28,7%) 4 (10,0%) Clinical Misscar. 1 (5,3%) 13 (14,6%) 14 (14,9%) 12 (30,0%) Ongoing/LBR 18 (48,7%) 69 (50,0%) 73 (37,1%) 28 (14,9%) OHSS (E+L) Total pos hcg/et 22 (66,7%) 90 (70,3%) 96 (55,5%) 48 (44,4%) Bioch.Preg I.R. 43,6% 51,6% 40,1% 29,7%
37 F.C.H. personal DATA D5 ET (7/ /2017) Age Group <= >= 40 Day3: CPR/ET 0/2 (0%) 13/19 (68,4%) 17/49 (34,7%) 13/33 (39,4%) Oocytes 7,50 7,05 7,41 7,64 Embryos/ET 1,00 1,58 1,57 1,33 Day 5:CPR/ET 18/27 (66,7%) 58/92 (63,0%) 56/96 (58,3%) 23/52 (44,2%) Oocytes 10,48 11,16 9,64 8,65 Embryos/ET 1,78 1,76 1,63 1,35
38 Progesterone (nmol/l) hcg miu/ml P4 (ng/ml) P4 & hcg levels in relation to oocyte pick-up: hcg l Natural cycle -5 0 Days after 5 OPU 10 HCG Start Dosis Tag 75 OPU+1 <1.2 <1.2 HCG mlu/ml E2 pg/ml P4 ng/ml 17 OHP µg/l OPU -2 OPU OPU +5 OPU +7 5,9 6.2 OPU -2 OPU OPU OPU OPU OPU OPU +5 OPU +7 0,9 5, OPU -2 OPU OPU +5 OPU
39 DAY 5 ET (FCH Data) Mean age 37,6 years Cycles C.Pregnancy Rate ET Day 5: Fresh Blastocyst ET % FET Blastocyst % FET 2PN->Blastocyst 68-57% All n.s.
40 Conclusions The luteal phase following a hcg trigger will induce - high levels of progesterone in the early luteal phase - reduced C.L. stimulation during the mid-luteal phase around implantation In COS a threshold value of P 4 of around nmol/l exists above which early pregnancy loss is reduced The agonist trigger allows a number of new luteal phase protocols to be tested A new regime using only daily 100 I.U. hcg s.c.from OPU+1 until OPU+9 is sufficent for LPS after GnRH-a ovulation triggeringshowing a P4 luteal phase pattern like the natural cycle and reduced pregnancy loss.
41 Thank you HAMBURG
A survey on luteal phase support:
A survey on luteal phase support: An IVF Worldwide Survey results I have no conflict of interest! The reason why luteal phase support is needed: The normal physiological support of the corpus luteum the
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationA rationale for timing of luteal support post GnRH agonist trigger. Address: IVF Unit, Elisha Hospital, 12 Yair Katz Street, Haifa, Israel,
Short Review: A rationale for timing of luteal support post GnRH agonist trigger Shahar Kol, IVF Unit, Elisha Hospital, Haifa, Israel. Address: IVF Unit, Elisha Hospital, 12 Yair Katz Street, Haifa, Israel,
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationEndometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY
Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:
More informationHow to make the best use of the natural cycle for frozen-thawed embryo transfer?
How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationNuoveprospettive per la faseluteale.
Nuoveprospettive per la faseluteale. Dr. Ilario Candeloro Centro di Procreazione Medicalmente Assistita ASST Papa Giovanni XXIII Bergamo The role of LH and progesterone in the luteal phase Totally responsible
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationEmbryo transfer and Luteal phase support
Embryo transfer and Luteal phase support PATCHARADA AMATYAKUL, M.D. DEPARTMENT OF OBSTETRICS AND GYNECOLOGY FACULTY OF MEDICINE NARESUAN UNIVERSITY Embryo Transfer http://www.regionalfertilityprogram.ca/program-embryotransfer.php
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationOvarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) OHSS OHSS: exaggerated response to gonadotropins and hcg Characterized by: ovarian enlargement increased vascular permeability fluid accumulation in abdomen Associated
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological
More informationComparison of GnRH agonist with low-dose urinary hcg for induction of final oocyte maturation
Basrah Journal Of Surgery COMPARISON OF GNRH AGONIST WITH LOW-DOSE URINARY HCG FOR THE INDUCTION OF FINAL OOCYTE MATURATION IN HIGH-RISK PATIENTS UNDERGOING INTRACYTOPLASMIC SPERM INJECTION-EMBRYO TRANSFER
More informationUniversal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.
Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationHCG mode of action versus GnRHa action for triggering of final oocyte maturation
HCG mode of action versus GnRHa action for triggering of final oocyte maturation Nick Macklon Professor of Obstetrics and Gynaecology, University of Southampton A hammer to crack a nut hcg? How hard does
More informationOvarian hyperstimulation syndrome- an optimal solution for an unresolved enigma
Orvieto Journal of Ovarian Research 2013, 6:77 REVIEW Open Access Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma Raoul Orvieto 1,2 Abstract Ovarian hyperstimulation syndrome
More informationRaoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest
Raoul Orvieto The Chaim Sheba Medical Center Tel Hashomer, Israel Declared no potential conflict of interest LH in antagonist cycles; is the story really written? Raoul Orvieto M.D. Israel Overview Role
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationAre all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes?
Are all-freeze cycles & frozen-thawed embryo transfers improving IVF outcomes? Andrea Weghofer Foundation for Reproductive Medicine 2017 New York, November 16-19 Conflict of interest No relevant financial
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationMinimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology
Minimising IVF related mortality and morbidity Scott Nelson Muirhead Professor in Obstetrics & Gynaecology We rarely say no - so what I will cover today VTE as an example of a modifiable IVF complication
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationestrogen supplementation for luteal phase support.
Rationale and regimens of progesterone and estrogen supplementation for luteal phase support. Cicinelli E. IV Dept. Ob/Gyn, University of Bari, Italy cicinelli@gynecology1.uniba.it Luteal phase defect
More informationDipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization
More informationHigh Peak Estradiol Predicts Higher Miscarriage and Lower Live Birth Rates in High Responders Triggered with a GnRH Agonist in IVF/ICSI Cycles
The Journal of Reproductive Medicine High Peak Estradiol Predicts Higher Miscarriage and Lower Live Birth Rates in High Responders Triggered with a GnRH Agonist in IVF/ICSI Cycles Ryan G. Steward, M.D.,
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationThrombosis during assisted reproduction. Scott Nelson Muirhead Chair in Obstetrics & Gynaecology
Thrombosis during assisted reproduction Scott Nelson Muirhead Chair in Obstetrics & Gynaecology ART can be as safe as natural pregnancy!! What used to be the risk of thrombosis in ART!! We can use AMH
More informationScientific Highlights: First world conference on luteinizing hormone in ART: Landing in Asia Pacific
This EXCEMED conference followed on from the First world conference on luteinizing hormone (LH) in ART, which took place in Naples in May 2016. Bringing the topic of LH to Asia Pacific provided an opportunity
More informationAOGS COMMENTARY SHAHAR KOL 1, ROY HOMBURG 2,3, BIRGIT ALSBJERG 4 & PETER HUMAIDAN 5. Abstract
A C TA Obstetricia et Gynecologica AOGS COMMENTARY The gonadotropin-releasing hormone antagonist protocol the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More informationPresident : Indian Society for Assisted Reproduction (ISAR) Past President FOGSI. Past Chairman ICOG. Founder Trustee Women s Empowerment Foundation
Founder President: The PCOS Society, India Honorary Fellow of the Royal College of Obst.& Gyn. Prof.Duru Shah President : Indian Society for Assisted Reproduction (ISAR) Past President FOGSI. Past Chairman
More informationDr. Madhuri Patil. M.D., DGO, FCPS, DFP, FICOG. (Mum) Dr. Patil s Fertility & Endoscopy Clinic Bangalore
OHSS Have we found a solution? Dr. Madhuri Patil M.D., DGO, FCPS, DFP, FICOG. (Mum) Dr. Patil s Fertility & Endoscopy Clinic Bangalore Ovarian hyperstimulation syndrome Serious and detrimental complication
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationDisclosure. Lyubov Mykhaylshyn IVF department Alternativa clinic Lviv, Ukraine
Disclosure Lyubov Mykhaylshyn IVF department Alternativa clinic Lviv, Ukraine I do not currently have, nor have I had in the 12 months preceding the activity, a vested interest or affiliation with any
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationEvaluation of an optimal luteal phase support protocol in IVF
Acta Obstet Gynecol Scand 2001; 80: 452 466 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationModified natural cycles: the Italian experience
CLINICA VALLE GIULIA, Rome Modified natural cycles: the Italian experience Filippo Maria Ubaldi M.D. M.Sc. Poor ovarian Response ESHRE Campus symposium Bologna 19-20 March 2010 Introduction Ovarian superovulation
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationL2. Optimising IVF outcomes through increased number of oocytes... 03
SCIENTIFIC HIGHLIGHTS EXCEMED Blended Education Ovarian stimulation strategies: maximizing efficiency in ART Rio de Janeiro, Brazil 6-7 April 2018 Preface Success rates following IVF treatment have increased
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationCONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS. DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA
CONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA LEARNING OBJECTIVE Introduction Ovarian stimulation protocols Comparison of different
More information1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.
1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH. 2. This causes the anterior pituitary to secrete small quantities of FSH and LH. 3. At this time, the follicles in the
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationGnRH agonist triggering: recent developments
Reproductive BioMedicine Online (2013) 26, 226 230 www.sciencedirect.com www.rbmonline.com REVIEW GnRH agonist triggering: recent developments Shahar Kol a, *, Peter Humaidan b a Department of Obstetrics
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationE.G. Papanikolaou 1,2,3, *, G. Pados 1,3, G. Grimbizis 1,3, E. Bili 1,3, L. Kyriazi 3, N.P. Polyzos 4,P.Humaidan 5,H.Tournaye 4,andB.
Human Reproduction, Vol.27, No.6 pp. 1822 1828, 2012 Advanced Access publication on March 14, 2012 doi:10.1093/humrep/des066 ORIGINAL ARTICLE Reproductive endocrinology GnRH-agonist versus GnRH-antagonist
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationThe Human Menstrual Cycle
The Human Menstrual Cycle Name: The female human s menstrual cycle is broken into two phases: the Follicular Phase and the Luteal Phase. These two phases are separated by an event called ovulation. (1)
More informationJournal of Gynecology & Reproductive Medicine
Research Article Journal of Gynecology & Reproductive Medicine Ovarian Hyperstimulation Syndrome Ratio And In Vitro Fertilization Success With Gonadotrphine Releasing Hormone Trigger And 1500 IU Human
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationProgesterone Vaginal Ring for Luteal Support
The Journal of Obstetrics and Gynecology of India (January February 2015) 65(1):5 10 DOI 10.1007/s13224-014-0634-0 INVITED REVIEW ARTICLE Progesterone Vaginal Ring for Luteal Support Stadtmauer Laurel
More informationProgesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles
ORIGINAL PAPER / OBSTETRICS Ginekologia Polska 2016, vol. 87, no. 5, 372 377 Copyright 2016 Via Medica ISSN 0017 0011 DOI: 10.5603/GP.2016.0007 Progesterone vaginal capsule versus vaginal gel for luteal
More informationKey words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct
Human Reproduction Vol.20, No.10 pp. 2887 2892, 2005 Advance Access publication June 24, 2005. doi:10.1093/humrep/dei150 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering
More informationWhat is the POSEIDON concept?
Improving Success in ART: how to define it and key strategies to get the best outcomes, Kiev, 21-09-2018 What is the POSEIDON concept? Alessandro Conforti Italy Objectives Unravel the definition of POR
More informationN. Shirazian, MD. Endocrinologist
N. Shirazian, MD Internist, Endocrinologist Inside the ovary Day 15-28: empty pyfollicle turns into corpus luteum (yellow body) Immature eggs Day 1-13: 13: egg developing inside the growing follicle Day
More informationSerum progesterone levels on the day of hcg trigger and ICSI outcome: a retrospective observational cohort study
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Amin KV et al. Int J Reprod Contracept Obstet Gynecol. 2018 Aug;7(8):3194-3198 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20183316
More informationHow do we choose the best progesterone to support the luteal phase
How do we choose the best progesterone to support the luteal phase Prof. Dr. Herman Tournaye MSD Fertility Regional Stand Alone Scientific Symposium Lisbon In the last 3 years the speaker or the speaker
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationThe effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles
Original Article Obstet Gynecol Sci 2014;57(4):291-296 http://dx.doi.org/10.5468/ogs.2014.57.4.291 pissn 2287-8572 eissn 2287-8580 The effect of luteal phase progesterone supplementation on natural frozen-thawed
More informationVaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer
Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer Mohamed F. Mitwally, M.D., H.C.L.D., a Michael P. Diamond,
More informationIncreasing vaginal progesterone gel supplementation after frozen thawed embryo transfer significantly increases the delivery rate
Reproductive BioMedicine Online (2013) 26, 133 137 www.sciencedirect.com www.rbmonline.com ARTICLE Increasing vaginal progesterone gel supplementation after frozen thawed embryo transfer significantly
More informationArticle Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study
RBMOnline - Vol 15. No 2. 2007 134-148 Reproductive BioMedicine Online; www.rbmonline.com/article/2711 on web 13 June 2007 Article Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective
More informationAdvanced age, poor responders and the role of LH supplementation. C. Alviggi University Federico II, Naples, Italy
Advanced age, poor responders and the role of LH supplementation C. Alviggi University Federico II, Naples, Italy LH serum level (IU/L) 20.0 15.0 10.0 5.0 0.0 LH levels during spontaneous and stimulated
More information(1.,, ) (2.,,, )
33 11 Vol.33 No.11 2013 11 Nov. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.11.0749 E-mail: randc_journal@163.com IVF-ET 1 2 1 1 1 1 1 (1. 510150) (2. 510150) : (COH) (premature
More informationGnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study
Human Reproduction Vol.21, No.7 pp. 1894 1900, 2006 Advance Access publication March 23, 2006. doi:10.1093/humrep/del072 GnRH agonist as luteal phase support in assisted reproduction technique cycles:
More informationInvestigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?
Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle? Introduction: The menstrual cycle (changes within the uterus) is an approximately 28-day cycle that
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationData collected through IVF- Worldwide.com
Data collected through IVF- Worldwide.com Science vs. Clinical Practice Zeev Shoham, MD Director of the Reproductive Medicine and IVF Unit Department Ob/Gyn, Kaplan Medical Center Rehovot, Israel 1 Evidence
More informationEffects of HCG and LH on ovarian stimulation. Are they bioequivalent?
Effects of HCG and LH on ovarian stimulation Are they bioequivalent? Know the type of gonadotrophin required to have enough oocytes of good quality to achieve a healthy child FSH MAXIMIZE EFFICIENCY MINIMIZE
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More informationSpontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study
Reproductive BioMedicine Online (2011) 23, 484 489 www.sciencedirect.com www.rbmonline.com ARTICLE Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationInt J Clin Exp Med 2015;8(10): /ISSN: /IJCEM Pin-Xiu Huang, Ji-Hong Wei, Li-Hong Wei
Int J Clin Exp Med 2015;8(10):19072-19078 www.ijcem.com /ISSN:1940-5901/IJCEM0014127 Original Article Gonadotropin-releasing hormone agonist for oocyte triggering in endometrial preparation of letrozole
More informationERA. Endometrial Receptivity Analysis. Patented since
Endometrial Receptivity Analysis Patented since 2009 www.igenomix.com ERA ERA analyzes by NGS the expression of 236 genes in order to determine the personalized window of implantation for each patient.
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationIN VITRO FERTILIZATION
FERTILITY AND STERILITY VOL. 72, NO. 5, NOVEMBER 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION
More informationREPRODUCCIÓN. La idea fija. Copyright 2004 Pearson Education, Inc., publishing as Benjamin Cummings
REPRODUCCIÓN La idea fija How male and female reproductive systems differentiate The reproductive organs and how they work How gametes are produced and fertilized Pregnancy, stages of development, birth
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationPersonalizing ovarian stimulation for IVF
Personalizing ovarian stimulation for IVF Biljana Popovic-Todorovic MD,PhD Centre for Reproductive Medicine UZ Brussel QuickTime and are needed to see this picture. Controlled ovarian stimulation for IVF/ICSI
More informationNo influence of the indication of freeze-all strategy on subsequent outcome to frozen-thawed embryo transfer cycle
Original paper No influence of the indication of freeze-all strategy on subsequent outcome to frozen-thawed embryo transfer cycle T. Masschaele 1,2, F. VandekerckhoVe 2, P. de sutter 2, J. Gerris 2 1 AZ
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationPhases of the Ovarian Cycle
OVARIAN CYCLE An ovary contains many follicles, and each one contains an immature egg called an oocyte. A female is born with as many as 2 million follicles, but the number is reduced to 300,000 to 400,000
More informationORIGINAL ARTICLE Early pregnancy
Human Reproduction, Vol.26, No.5 pp. 1020 1024, 2011 Advanced Access publication on February 4, 2011 doi:10.1093/humrep/der012 ORIGINAL ARTICLE Early pregnancy Does cessation of progesterone supplementation
More informationIVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW
IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation
More information